Expertise in
3
conditions

Dr. Melissa Bear

Hematology | Oncology
Riley Hospital For Children At Indiana University Health
705 Riley Hospital Dr, 
Indianapolis, IN 
Clinical Trials:Currently Recruiting for 3 Trials
Expertise in
3
conditions
Riley Hospital For Children At Indiana University Health
705 Riley Hospital Dr, 
Indianapolis, IN 

Overview

Melissa Bear is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana.

Dr. Bear is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Ewing Sarcoma, and Osteosarcoma.

She is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 15 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in IN

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
View 2 Less Insurance Carriers -

Locations

Riley Hospital for Children at Indiana University Health
705 Riley Hospital Dr, Indianapolis, IN 46202

Additional Areas of Focus

Dr. Bear has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Enrollment Status: Recruiting
Publish Date: May 05, 2026
Intervention Type: Radiation, Drug, Procedure
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Topotecan, Vincristine
Study Phase: Phase 2
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma
Enrollment Status: Recruiting
Publish Date: May 05, 2026
Intervention Type: Drug, Procedure
Study Drug: FACT Complex-Targeting Curaxin CBL0137
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Enrollment Status: Recruiting
Publish Date: May 05, 2026
Intervention Type: Procedure, Drug
Study Drug: Tegavivint
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of DS-8201a (NSC# 807708) in Children, Adolescents, or Young Adults With Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
A Phase 1/2 Study of DS-8201a (NSC# 807708) in Children, Adolescents, or Young Adults With Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
Enrollment Status: Suspended
Publish Date: June 18, 2026
Intervention Type: Procedure, Biological
Study Drug: Trastuzumab Deruxtecan
Study Phase: Phase 1/Phase 2
A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Drug, Biological
Study Drugs: Cytarabine, Flotetuzumab
Study Phase: Phase 1
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
Enrollment Status: Completed
Publish Date: May 11, 2026
Intervention Type: Drug
Study Drugs: Ramucirumab, Cyclophosphamide, Vinorelbine
Study Phase: Phase 1/Phase 2
A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors
A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2026
Intervention Type: Drug
Study Drug: Elimusertib
Study Phase: Phase 1/Phase 2
A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: April 13, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, Cytarabine, Fludarabine Phosphate, Methotrexate, Pevonedistat, Hydrocortisone
Study Phase: Phase 1
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Other
Study Drug: Selinexor
Study Phase: Phase 1
A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan
A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Other
Study Phase: Phase 1
View 7 Less Clinical Trials

4 Total Publications

The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial.
The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial.
Journal: Nature communications
Published: January 19, 2024
Similar Doctors
Expertise in
6
conditions
Dr. Amy Shapiro
Hematology | Oncology
Expertise in
6
conditions
Dr. Amy Shapiro
Hematology | Oncology
Referral may be required

Indiana Hemophilia And Thrombosis Center Inc

8326 Naab Rd, 
Indianapolis, IN 
 (9.0 miles away)
317-871-0000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amy Shapiro is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Shapiro is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Blood Clots, Hemophilia A, Hemophilia B, and Ligneous Conjunctivitis.

Expertise in
30
conditions
Dr. Daniel Rushing
Hematology | Oncology
Expertise in
30
conditions
Dr. Daniel Rushing
Hematology | Oncology
Referral may be required

Univ. Radiation Oncology Associates Inc.

535 Barnhill Dr, 
Indianapolis, IN 
 (0.2 miles away)
317-948-8310
Languages Spoken:
English
See accepted insurances

Daniel Rushing is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Rushing is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Epithelioid Sarcoma, and Fibrosarcoma.

Expertise in
9
conditions
Dr. Seethal Jacob
Hematology | Oncology
Expertise in
9
conditions
Dr. Seethal Jacob
Hematology | Oncology
Referral may be required

Office

575 Riley Hospital Dr Ste 3270, 
Indianapolis, IN 
 (1.0 miles away)
317-944-2143
Experience:
17+ years
Languages Spoken:
English
See accepted insurances

Seethal Jacob is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana. She has been practicing medicine for over 17 years. Dr. Jacob is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia.

Frequently Asked Questions about Dr. Melissa Bear

How do I make an appointment with Dr. Melissa Bear?

You can book an appointment with Dr. Melissa Bear by calling their office at 317-944-2143. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Melissa Bear a top-rated expert for Neuroblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Melissa Bear is classified as an Distinguished expert for Neuroblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Melissa Bear specialize in?

While Dr. Melissa Bear is a Hematology, they have specific expertise in Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Ewing Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Melissa Bear participate in research or clinical trials?

Yes. Dr. Melissa Bear has published 4 articles and abstracts on conditions like Neuroblastoma. You can view a list of Dr. Melissa Bear's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Melissa Bear accept my insurance?

Dr. Melissa Bear accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 317-944-2143 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bear's expertise for a condition
ConditionClose
    View All 22 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile